Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06524973 · ClinicalTrials.gov registry record · NA
Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers
A NA study of Metastatic Pancreatic Adenocarcinoma, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 136
- Enrollment target
- 20
- Study locations
NCT06524973 is a NA study of Metastatic Pancreatic Adenocarcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 136 participants, above the 86-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (58% higher). The trial reports 20 study locations across 1 state.
The verdict
NCT06524973, a NA study of Metastatic Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 136 participants
- Enrollment target
- 20
- Study locations
Study Summary
This clinical trial evaluates the impact of telehealth self-management coaching sessions on quality of life in pancreatic cancer survivors and their family care givers (FCGs). Patients with pancreatic cancer experience many symptoms because of the disease and treatment, which can have a negative impact on quality of life. Patients and their families have unmet needs during treatment, including a lack of quality of life programs that offer support to patients. Supporting patients and families on managing the physical symptoms, emotional well-being, social well-being and spiritual well-being with telehealth self-management coaching sessions may help improve quality of life, manage symptoms from treatment, and support families in their role as caregivers during treatment.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Best Practice
- OTHER Counseling
- OTHER Telemedicine
- OTHER Inrweview
Study Locations (20)
California
- City of Hope at Arcadia - Arcadia
- City of Hope Corona - Corona
- City of Hope at Duarte - Duarte
- City of Hope Comprehensive Cancer Center - Duarte
- City of Hope at Glendale - Glendale
- City of Hope at Glendora - Glendora
- City of Hope Seacliff - Huntington Beach
- City of Hope at Irvine Lennar - Irvine
- City of Hope at Irvine Sand Canyon - Irvine
- City of Hope Antelope Valley - Lancaster
- City of Hope at Long Beach Worsham - Long Beach
- City of Hope at Long Beach Elm - Long Beach
- City of Hope Mission Hills - Mission Hills
- City of Hope at Newport Beach Fashion Island - Newport Beach
- City of Hope at Palmdale - Palmdale
- City of Hope - Santa Clarita - Santa Clarita
- City of Hope at Simi Valley - Simi Valley
- City of Hope South Pasadena - South Pasadena
- City of Hope at Thousand Oaks - Thousand Oaks
- City of Hope South Bay - Torrance
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2024-10-07 |
| Est. Completion | 2027-05-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06524973
The ClinicalTrials.gov registry entry for NCT06524973 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 86-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (58% higher). The listed sponsor is City of Hope Medical Center, which has 582 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metastatic Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Questionnaire Administration is the first listed.
NCT06524973 reports 20 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06524973 about?
NCT06524973 is a clinical study titled "Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers". This clinical trial evaluates the impact of telehealth self-management coaching sessions on quality of life in pancreatic cancer survivors and their family care givers (FCGs). Patients with pancreatic cancer experience many symptoms because of the disease and treatment, which can have a negative imp...
What is the current status of trial NCT06524973?
This trial is currently recruiting. It is a NA study. The enrollment target is 136 participants. The study started on 2024-10-07. Estimated completion is 2027-05-03.
What conditions does trial NCT06524973 study?
This clinical trial studies the following conditions: Metastatic Pancreatic Adenocarcinoma.
What interventions are being tested in trial NCT06524973?
The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Counseling (OTHER), Telemedicine (OTHER), Inrweview (OTHER).
Who is sponsoring clinical trial NCT06524973?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06524973 being conducted?
This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Pancreatic Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Medical Food for the Dietary Management of Advanced/Metastatic Pancreatic Cancer
COMPLETED · NA
-
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
RECRUITING · Phase 1
-
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
RECRUITING · Phase 3
-
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
RECRUITING · Phase 2
-
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.